131 related articles for article (PubMed ID: 15452025)
1. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
Li Z; Iwai M; Wu L; Liu HW; Chen R; Jinno T; Suzuki J; Tsuda M; Gao XY; Okumura M; Cui TX; Horiuchi M
Hypertension; 2004 Nov; 44(5):758-63. PubMed ID: 15452025
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
Horiuchi M; Cui TX; Li Z; Li JM; Nakagami H; Iwai M
Circulation; 2003 Jan; 107(1):106-12. PubMed ID: 12515751
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
5. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
Iwai M; Chen R; Li Z; Shiuchi T; Suzuki J; Ide A; Tsuda M; Okumura M; Min LJ; Mogi M; Horiuchi M
Circulation; 2005 Sep; 112(11):1636-43. PubMed ID: 16145000
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.
Tsuda M; Iwai M; Li JM; Li HS; Min LJ; Ide A; Okumura M; Suzuki J; Mogi M; Suzuki H; Horiuchi M
Hypertension; 2005 Apr; 45(4):545-51. PubMed ID: 15723967
[TBL] [Abstract][Full Text] [Related]
7. [Influence of valsartan, fluvastatin extended release and their combination on arterial pressure, parameters of lipid metabolism, and endothelial function in patients with hypertensive disease].
Soboleva GN; Pogorelova OA; Kuznetsova TV; Masenko VP; Fomicheva OA; Chernova NA; Rogoza AN; Balakhonova TV; Karpov IuA
Kardiologiia; 2007; 47(11):9-13. PubMed ID: 18260957
[TBL] [Abstract][Full Text] [Related]
8. Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Aono J; Suzuki J; Iwai M; Horiuchi M; Nagai T; Nishimura K; Inoue K; Ogimoto A; Okayama H; Higaki J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1453-9. PubMed ID: 22460554
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Suzuki J; Iwai M; Mogi M; Oshita A; Yoshii T; Higaki J; Horiuchi M
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):917-21. PubMed ID: 16424347
[TBL] [Abstract][Full Text] [Related]
11. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
Hussein O; Shneider J; Rosenblat M; Aviram M
J Cardiovasc Pharmacol; 2002 Jul; 40(1):28-34. PubMed ID: 12072574
[TBL] [Abstract][Full Text] [Related]
12. A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males.
Janić M; Lunder M; Prezelj M; Šabovič M
J Cardiopulm Rehabil Prev; 2014; 34(3):208-12. PubMed ID: 24263076
[TBL] [Abstract][Full Text] [Related]
13. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
14. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
Tomono Y; Iwai M; Inaba S; Mogi M; Horiuchi M
Am J Hypertens; 2008 Feb; 21(2):206-12. PubMed ID: 18188158
[TBL] [Abstract][Full Text] [Related]
15. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits.
Mitani H; Egashira K; Ohashi N; Yoshikawa M; Niwa S; Nonomura K; Nakashima A; Kimura M
Pharmacology; 2003 Jul; 68(3):121-30. PubMed ID: 12784083
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice.
Yao R; Cheng X; Chen Y; Xie JJ; Yu X; Liao MY; Ding YJ; Tang TT; Liao YH
Int J Cardiol; 2010 Mar; 139(2):113-22. PubMed ID: 19028402
[TBL] [Abstract][Full Text] [Related]
17. [The effect of captopril and valsartan on preventing the formation of atherosclerotic plaque].
Lu YS; Lei XY; DI J; Huang ST; Li JM
Zhonghua Nei Ke Za Zhi; 2005 Jun; 44(6):425-7. PubMed ID: 16008853
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
19. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.
Yoshii T; Iwai M; Li Z; Chen R; Ide A; Fukunaga S; Oshita A; Mogi M; Higaki J; Horiuchi M
Hypertens Res; 2006 Jun; 29(6):457-66. PubMed ID: 16940709
[TBL] [Abstract][Full Text] [Related]
20. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
